title: [Anti-high mobility group box-1 antibody therapy for traumatic brain injury].
abstract: Traumatic brain injury (TBI) is one of the major causes of death and aftereffects in young individuals worldwide; however, efficient therapies for TBI are lacking at present. High mobility group box-1 (HMGB-1), which is recognized as a representative of danger-associated molecular patterns (DAMPs), plays an important role in triggering inflammatory responses in many types of diseases. We presented the involvement of HMGB-1 in TBI and evaluated the ability of intravenously administered neutralizing anti-HMGB-1 monoclonal antibody (mAb) to attenuate brain injury. Anti-HMGB-1 mAb may provide a novel and effective therapy for TBI by protecting against blood brain barrier disruption and reducing the inflammatory responses induced by HMGB-1.
authors.affiliation: Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
authors.forename: Yu
authors.initials: Y
authors.lastname: Okuma
authors.forename: Isao
authors.initials: I
authors.lastname: Date
authors.forename: Masahiro
authors.initials: M
authors.lastname: Nishibori
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D017209:Apoptosis; D001812:Blood-Brain Barrier; D001930:Brain Injuries / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D024243:HMGB1 Protein / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D021381:Protein Transport
chemical_list: D000911:Antibodies, Monoclonal; D024243:HMGB1 Protein